Use of DF3/MUC1 regulated expression in gene therapy
AssigneesThe University of Chicago, Dana-Farber Cancer Institute, Inc.
InventorsRalph R. Weichselbaum, Donald W. Kufe
Life of this patent
Estimating the term…
Abstract
The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3/MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.
Claims2
A method for enhancing radiosensitivity of a cancer cell expressing DF3/MUC1 glycoprotein, comprising directly administering to the cancer cell an adenoviral vector comprising a first polynucleotide sequence encoding E1A operably linked to a MUC1 promoter and a second polynucleotide sequence encoding TNF-α operably linked to a CMV promoter;
- and irradiating the cancer cell.
Dependencies are inferred from the claim text.